title: CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation?
authors.affiliation: Section of Psychiatry and Clinical Psychology, University of Verona, Policlinico GB Rossi, Piazzale Scuro 10, 37134, Verona, Italy. corrado.barbui@univr.it
authors.forename: Corrado
authors.initials: C
authors.lastname: Barbui
authors.forename: Andrea
authors.initials: A
authors.lastname: Cipriani
authors.forename: Camilla
authors.initials: C
authors.lastname: Lintas
authors.forename: Vittorio
authors.initials: V
authors.lastname: Bertelé
authors.forename: Silvio
authors.initials: S
authors.lastname: Garattini
mesh_terms: D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence*; D004059:Diffusion of Innovation; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D064420:Drug-Related Side Effects and Adverse Reactions; D005060:Europe; D005062:European Union; D006801:Humans; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D011785:Quality Assurance, Health Care / Q000331:legislation & jurisprudence; D016896:Treatment Outcome
chemical_list: D011619:Psychotropic Drugs